H.C. Wainwright Reaffirms Their Buy Rating on Precision BioSciences (DTIL)
at www.tipranks.com (Wed, 29-Apr 6:37 AM)
DTIL Extends Cash Runway Through 2028 on Strong Clinical Progress in Hepatitis B and Duchenne Muscular Dystrophy Programs
Market Chameleon (Thu, 12-Mar 7:50 AM)
FDA Fast Track Approval for PBGENE-DMD Spotlights Precision BioSciences’ Ambitious Gene Editing Push in Duchenne Muscular Dystrophy
Market Chameleon (Mon, 9-Mar 7:59 AM)
